Ribavirin therapy for Chikungunya arthritis

Area of Science:

• Virology
• Rheumatology
• Infectious Diseases

Background:

• Chikungunya virus infection causes acute febrile illness with severe joint pain.
• Persistent arthritis and soft tissue swelling can impair patient mobility.
• Current treatments are largely symptomatic, with limited options for chronic manifestations.

Purpose of the Study:

• To evaluate the efficacy of the antiviral drug Ribavirin in patients with persistent Chikungunya-related arthritis.
• To assess the impact of Ribavirin on pain, swelling, and mobility in affected individuals.

Main Methods:

• A randomized study involving 10 patients with persistent Chikungunya lower limb pain and arthritis.
• A control group of 10 similar patients was observed.
• The treatment group received Ribavirin (200 mg twice daily for seven days).
• Both groups were monitored for four weeks.

Main Results:

• Significant improvement in joint pain was reported by all patients in the Ribavirin group.
• Six patients in the treatment group regained free mobility.
• Soft tissue swelling decreased in eight patients.
• Seven patients no longer required analgesics after four weeks.

Conclusions:

• Ribavirin demonstrates potential antiviral activity against Chikungunya virus.
• The drug may accelerate the resolution of joint and soft tissue symptoms associated with Chikungunya.
• Further research is warranted to confirm Ribavirin's therapeutic role.